Active substancePregabalinPregabalin
Similar drugsTo uncover
  • Algerika
    capsules inwards 
  • Lyrics®
    capsules inwards 
    Pfizer Inc.     USA
  • Prabegin®
    capsules inwards 
  • Pregabalin
    capsules inwards 
    GEROPHARM, LLC     Russia
  • Pregabalin
    capsules inwards 
  • Pregabalin Zentiva
    capsules inwards 
    Zentiva c.s.     Czech Republic
  • Pregabalin Canon
    capsules inwards 
  • Pregabalin-native
    capsules inwards 
    NATIVA, LLC     Russia
  • Pregabalin-Richter
    capsules inwards 
    GEDEON RICHTER, OJSC     Hungary
  • Pregabalin-SZ
    capsules inwards 
    NORTH STAR, CJSC     Russia
  • Prigabilon
    capsules inwards 
  • Replica
    capsules inwards 
    ARS, LLC     Russia
  • Dosage form: & nbspcapsules
    Composition:

    One capsule contains:

    Dosage of 25 mg:

    active substance: pregabalin 25 mg;

    Excipients: starch corn pregelatinized 42 mg, mannitol 30 mg, magnesium stearate 1 mg, talc 2 mg;

    hard gelatin capsule № 3: 48 mg, including body: titanium dioxide 0.6052 mg, gelatin 29.6341 mg, dye indigotin 0.0207 mg; cap: titanium dioxide 0.3548 mg, gelatin 17.3731 mg, dye indigotine 0.0121 mg.

    Dosage 50 mg:

    active substance: pregabalin 50 mg;

    Excipients: starch corn pregelatinized 41.7 mg, mannitol 30 mg, magnesium stearate 1.1 mg, talc 2.2 mg;

    hard gelatin capsule № 3: 48 mg, including body: titanium dioxide 0.9078 mg, gelatin 29.1485 mg, quinoline yellow color 0.2017 mg, dye sunset yellow 0.002 mg; lid: titanium dioxide 0.5322 mg, gelatin 17,0884 mg, quinoline yellow dye 0,1182 mg, dye sunset yellow 0.0012 mg.

    Dosage of 75 mg:

    active substance: pregabalin 75 mg;

    Excipients: starch corn pregelatinized 47 mg, mannitol 33.5 mg, magnesium stearate 1.5 mg, talc 3 mg;

    hard gelatin capsule number 2: 61 mg, including housing: titanium dioxide 0.3811 mg, gelatin 37.3478 mg, iron oxide pigment oxide yellow 0.3811 mg; lid: titanium dioxide 0.2289 mg, gelatin 22.4322 mg, iron oxide dye yellow 0.2289 mg.

    Dosage of 100 mg:

    active substance: pregabalin 100 mg;

    Excipients: starch corn pregelatinized 49.5 mg, mannitol 35.1 mg, magnesium stearate 1.8 mg, talc 3.6 mg;

    hard gelatin capsule number 1: 16 mg, including body: titanium dioxide 0,9244 mg, gelatin 45,1668 mg, the dye is proprietary blue V 0.1288 mg; lid: titanium dioxide 0.5956 mg, gelatin 29.1014 mg, dye patented blue V 0.803 mg.

    Dosage of 150 mg:

    active substance: pregabalin 150 mg;

    Excipients: starch corn pregelatinized 54.3 mg, mannitol 38.8 mg, magnesium stearate 2.3 mg, talc 4.6 mg;

    hard gelatin capsule number 1: 16 mg, including body: titanium dioxide 0.9244 mg, gelatin 45.2956 mg; cap: titanium dioxide 0.3971 mg, gelatin 29.1077 mg, quinoline yellow color 0.2739 mg, dye sunset yellow 0.0013 mg.

    Dosage 200 mg:

    active substance: pregabalin 200 mg;

    Excipients: starch corn pregelatinized 53.6 mg, mannitol 38.3 mg, magnesium stearate 2.7 mg, talc 5.4 mg;

    hard gelatin capsule № 0: 96 mg, including body: titanium dioxide 1.18 mg, gelatin 57.82 mg; cap: titanium dioxide 0.74 mg, gelatin 36.26 mg.

    Dosage of 300 mg:

    active substance: pregabalin 300 mg;

    Excipients: starch corn pregelatinized 69 mg, mannitol 49.3 mg, magnesium stearate 3.9 mg, talc 7.8 mg;

    hard gelatin capsule № 0: 96 mg, including housing: titanium dioxide 0.7866 mg, gelatin 57.6681 mg, quinoline yellow dye 0.5427 mg, dye sunset yellow 0.0026 mg; cap: titanium dioxide 0.4933 mg, gelatin 36.1648 mg, dye quinoline yellow 0.3403 mg, dye sunset yellow 0.0016 mg.

    Description:

    Hard gelatin capsules:

    - No. 3, lid and body of blue color (dosage of 25 mg); lid and body yellow (50 mg dosage);

    - No. 2, lid and body of dark yellow color (dosage: 75 mg);

    - No. 1, lid and body of blue color (dosage of 100 mg); the body is white, the lid is yellow (150 mg);

    - No. 0, lid and body white (200 mg dosage);

    - No. 0, body and cap of yellow color (dosage 300 mg).

    Contents of capsules: a mixture of powders of almost white color with inclusions in the form of small pieces of compacted mass or a compacted mass of almost white color, crumbling when pressed lightly.

    Pharmacotherapeutic group:antiepileptic agent
    ATX: & nbsp

    N.03.A.X.16   Pregabalin

    Pharmacodynamics:

    The active substance is pregabalinum - analogue of gamma-aminobutyric acid (GABA) - (S) -3- (aminomethyl) -5-methylhexanoic acid - has antiepileptic and anticonvulsant activity.

    Mechanism of action

    It was found that pregabalinum is associated with an additional subunit (α2-delta protein) of potential-dependent calcium channels (calcium channels N- and P / O-type) in the central nervous system, irreversibly replacing [3H] -gabapentin. It is suggested that such binding can contribute to the manifestation of its analgesic and anticonvulsant effects.

    Pharmacokinetics:

    Parameters of pharmacokinetics of pregabalin in equilibrium in healthy volunteers, in patients with epilepsy, who received antiepileptic therapy, and in patients who received it for chronic pain syndromes, were similar.

    Suction

    After oral administration on an empty stomach pregabalinum quickly absorbed in the gastrointestinal tract (GIT), the maximum concentration (CmOh) pregabalinum in a blood plasma it is noted in 1 hour at single reception. Upon repeated admission, the time to reach the maximum plasma concentration (TmOh) pregabalin does not change. Bioavailability of pregabalin does not depend on the dose taken and is not less than 90%. With repeated administration of pregabalin, equilibrium concentrations are reached within 24-48 hours. Food intake decreases the rate of absorption of pregabalin. So while taking pregabalin with food TmOh increases by approximately 2.5 hours, and CmOh Pregabalin decreases by 25-30% (in comparison with the data obtained after taking pregabalin on an empty stomach). It should be noted that eating does not have a clinically significant effect on the overall absorption of pregabalin.

    Distribution

    The apparent volume of distribution of pregabalin after oral administration is approximately 0.56 l / kg. Pregabalin does not bind to plasma proteins. Pregabalin well penetrates through the BBB and hematoplacental barrier, and also excreted in breast milk.

    Metabolism

    Pregabalinum is practically not exposed to a metabolism. After taking labeled pregabalin, approximately 98% of the radioactive label was detected in the urine unchanged. A small part of pregabalin (0.9% of the dose) is metabolized with formation Nmethylated compound, which is the main metabolite and is excreted through the kidneys. There were no signs of racemization Senantiomer of pregabalin in R-enantiomer.

    Excretion

    Pregabalin is excreted mainly by the kidneys in unchanged form. The average half-life is 6.3 hours. The clearance of pregabalin from the plasma and the renal clearance are directly proportional to the creatinine clearance (see Fig."Renal function disorder"). In patients with impaired renal function and patients on hemodialysis, dose adjustment is necessary (see the section "Method of administration and dose" of Table 1).

    Linearity / nonlinearity

    The pharmacokinetics of pregabalin in the range of recommended daily doses is linear, interindividual variability is low (<20%). Pharmacokinetics

    Pregabalin with repeated application can be predicted on the basis of single dose data. Consequently, there is no need for regular monitoring of pregabalin concentrations.

    Pharmacokinetics in special groups

    Floor

    The sex of the patient does not have a clinically significant effect on the concentration of pregabalin in plasma.

    Impaired renal function

    The clearance of pregabalin is directly proportional to the creatinine clearance. Given that pregabalinum is mainly excreted by the kidneys, in patients with impaired renal function it is recommended to reduce the dose of pregabalin. Besides, pregabalinum is effectively removed from the plasma during hemodialysis (after a 4-hour hemodialysis session, pregabalin plasma concentrations are reduced by approximately 50%), after hemodialysis it is necessary to prescribe an additional dose of the drug (see the section "Method of administration and dose" of Table 1).

    Impaired liver function

    Disturbance of liver function does not significantly affect the pharmacokinetics of pregabalin.

    Elderly patients (over 65 years of age)

    Clearance of pregabalin with age tends to decrease, which reflects the age-related decrease in creatinine clearance. Elderly people with impaired renal function may need to reduce the dose of the drug (see section "Method of administration and dose" of Table 1).

    Indications:

    Neuropathic pain

    Treatment of central and peripheral neuropathic pain in adults.

    Epilepsy

    As an additional therapy in adults with partial seizures, accompanied or not accompanied by secondary generalization.

    Generalized anxiety disorder

    Treatment of generalized anxiety disorder in adults.

    Fibromyalgia

    Treatment of fibromyalgia in adults.

    Contraindications:

    Hypersensitivity to the active substance or any other component of the drug.

    Children and adolescence under 18 years (no application data).

    Carefully:

    - Impaired renal function;

    - heart failure;

    - elderly patients (over 65 years);

    - An encephalopathy in the anamnesis;

    - diabetes;

    - simultaneous use with lorazepam, ethanol, oxycodone;

    - drug dependence in the anamnesis.

    Pregnancy and lactation:

    There is no reliable data on the efficacy and safety of pregabalin in pregnancy. When used in animals, the drug had a toxic effect on reproductive function. In this regard, the preparation Pregabalin Canon can be used during pregnancy only if the benefit to the mother clearly outweighs the possible risk to the fetus. In the treatment with Pregabalin Canon, women of reproductive age should use adequate methods of contraception.

    There is no information about the excretion of pregabalin with breast milk in women. However, in experimental studies it has been established that pregabalinum is excreted in breast milk in rats. In this regard, during treatment with Pregabalin Canon, breastfeeding is recommended to be suspended.

    Dosing and Administration:

    Inside, regardless of food intake.

    The drug is used in a dose of 150 to 600 mg / day in two or three doses. The capsule should be swallowed whole, without chewing and grinding, with enough water.

    The duration of treatment and the dose of the drug Pregabalin Canon is determined by the attending physician individually for each patient, depending on the nature of the disease and the individual characteristics of the patient.

    Neuropathic pain

    Treatment with Pregabalin Canon begins with a dose of 150 mg / day divided into 2 or 3 doses. Depending on the effect achieved and tolerance in 3-7 days, the dose can be increased to 300 mg / day, and, if necessary, after 7 days - up to a maximum dose of 600 mg / day.

    Epilepsy

    Treatment with Pregabalin Canon begins with a dose of 150 mg / day divided into 2 or 3 doses. Taking into account the achieved effect and tolerability after 1 week, the dose can be increased to 300 mg / day, and in a week - up to a maximum dose of 600 mg / day.

    Fibromyalgia

    Treatment with Pregabalin Canon begins with a dose of 150 mg per day divided by

    2 or 3 reception. Depending on the effect achieved and the tolerance in 3-7 days, the dose can be increased to 300 mg / day. In the absence of a positive effect, the dose is increased to 450 mg / day, and if necessary, after 7 days - up to a maximum dose of 600 mg / day.

    Generalized anxiety disorder

    Treatment with Pregabalin Canon begins with a dose of 150 mg / day divided into 2 or 3 doses. Depending on the effect achieved and the tolerability after 7 days, the dose can be increased to 300 mg / day. In the absence of a positive effect, the dose is increased to 450 mg / day, and if necessary, after 7 days - up to a maximum dose of 600 mg / day.

    Abolition of the drug Pregabalin Canon

    If treatment with Pregabalinum Kanon should be stopped, it is recommended to do this gradually for at least 1 week.

    Patients with impaired renal function

    In patients with impaired renal function, the dose is selected individually, taking into account the clearance of creatinine (CC) (see Table 1), which is calculated by the following formula:

    CK, ml / min = [140 - age in years] x body weight, kg x 0.85 for women / 72 x serum creatinine, mg / dL

    In patients receiving hemodialysis treatment, the daily dose of pregabalin is selected individually, taking into account the clearance of creatinine. Immediately after each 4-hour hemodialysis session, an additional dose is prescribed (see Table 1).

    Table 1. Selection of a dose of pregabalin with account of kidney function

    Clearance

    creatinine,

    ml / min

    Daily dose of pregabalinum

    Multiplicity of reception per day

    Starting dose, mg / day

    The maximum dose, mg / day

    More than 60

    150

    600

    2-3

    30 to 60

    75

    300

    2-3

    15 to 30

    25-50

    150

    1-2

    Less than 15

    25

    75

    1

    Additional dose after dialysis (mg)

    25

    100

    Once

    Use in patients with impaired liver function

    In patients with impaired liver function, dose adjustment is not required.

    Application in the elderly (over 65 years)

    Older people may need to reduce the dose of pregabalin due to a decrease in kidney function (see section "Pharmacokinetics")

    In case of missing a dose of Pregabalin Canon, the next dose should be taken as soon as possible, however, do not take the missed dose if the next time is appropriate.

    Side effects:

    According to the experience of clinical use of pregabalin in more than 12 000 patients, the most common adverse events were dizziness and drowsiness. The observed phenomena were usually mild or moderate. The main undesirable effects that required cessation of treatment were dizziness (4%) and drowsiness (3%), depending on their subjective tolerance. Other side effects that also lead to drug cancellation: ataxia, confusion, asthenia, impaired attention, blurred vision, impaired coordination, peripheral edema.

    The "cancellation" syndrome

    There are reports of cases of development of dependence when using pregabalin. As a result of cancellation of pregabalin after prolonged or short-term therapy, the following undesirable phenomena were observed: insomnia, headache, nausea, diarrhea, flu-like syndrome, depression, sweating, dizziness, convulsions and anxiety. Information on the frequency and severity of manifestations of the syndrome of "cancellation" of pregabalin, depending on the duration of therapy last and its dose is not available.

    Classification by WHO (World Health Organization) of the incidence of adverse events identified as a result of clinical trials and post-marketing surveillance: often from ≥1 / 100 to <1/10 of prescriptions (≥1% and <10%); infrequently - from ≥1 / 1000 to <1/100 of prescriptions (≥0.1% and <1%); rarely from ≥1 / 10,000 to <1/1000 appointments (≥0.01% and <0.1%); very rarely - <1/10000 prescriptions (0.01%);

    Infections and infestations: infrequently - nasopharyngitis.

    From the side of the blood and lymphatic system: infrequently - thrombocytopenia; rarely - Neutropenia, leukopenia.

    From the heart: infrequently - a tachycardia, an atrioventricular blockade of I degree; rarely - sinus tachycardia, sinus arrhythmia, sinus bradycardia; frequency unknown - chronic heart failure, prolongation of QT interval.

    From the side of the vessels: infrequently - "hot flashes", lowering blood pressure, increasing blood pressure, skin hyperemia; rarely - cold extremities.

    From the nervous system: very often - dizziness, drowsiness; often - ataxia, impaired attention, impaired coordination, memory impairment, tremor, dysarthria, paresthesia, imbalance, sedation, lethargy, headache; infrequently - cognitive disorders, hypoesthesia, nystagmus, speech disorders, myoclonic cramps, weakened reflexes, dyskinesia, postural dizziness, hypersthesia, amnesia, loss of taste sensations, burning sensation on the mucous membranes and skin, intentional tremor, stupor, fainting, psychomotor agitation; rarely - hypokinesia, parosmia, dysgraphy; frequency unknown - loss of consciousness, cognitive impairment, convulsions.

    From the side of the psyche: often - euphoria, confusion, decreased libido, insomnia, irritability, disorientation; infrequently - depersonalization, anorgasmia, anxiety, depression, agitation, lability of mood, depressed mood, difficulty in word selection, hallucinations, unusual dreams, increased libido,panic attacks, apathy; rarely - disinhibition, high spirits; frequency is unknown - aggression.

    From the side of the organ of vision: often - blurred vision, diplopia; infrequent - visual impairment: narrowing of the visual fields, reduced visual acuity, eye pain, asthenopia, dry eyes, puffiness of the eyes, increased lacrimation; rarely - flashes of sparks before the eyes, eye irritation, mydriasis, oscilloscopy (subjective sensation of fluctuations in the subjects under consideration), impaired perception of visual depth, loss of peripheral vision, strabismus, increased brightness of visual perception; frequency unknown - keratitis, loss of vision.

    From the side of the hearing organ and labyrinthine disorders: often - Vertigo; infrequently - Hyperacusis.

    From the digestive system: often - dry mouth, constipation, vomiting, flatulence; infrequent - bloating, increased salivation, gastroesophageal reflux, hypoesthesia of the oral mucosa; rarely - ascites, dysphagia, pancreatitis, tongue edema, nausea, diarrhea.

    On the part of the respiratory system, the organs of the thorax and the mediastinum: infrequently - shortness of breath, dryness of the nasal mucosa; rarely - stuffy nose, nosebleed, cough, rhinitis, snoring, a feeling of "restraint" in the throat; frequency unknown - pulmonary edema.

    From the musculoskeletal and connective tissues: infrequent - twitching of muscles, swelling of the joints, muscle spasms, myalgia, arthralgia, back pain, pain in the limbs, stiffness of the muscles; rarely - spasm of the neck muscles, neck pain, rhabdomyolysis.

    From the side of metabolism and nutrition: often - increased appetite, weight gain; infrequently - anorexia, hypoglycemia; rarely - weight loss.

    From the urinary system: infrequently - dysuria, incontinence; rarely - oliguria, renal insufficiency; frequency unknown - retention of urine.

    On the part of reproductive function: often - erectile disfunction; infrequently - delay of ejaculation, sexual dysfunction; rarely - amenorrhea, pain in the mammary glands, discharge from the mammary glands, dysmenorrhea, enlargement of mammary glands in the volume; frequency unknown - gynecomastia.

    From the immune system: frequency unknown - angioedema, allergic reactions, hypersensitivity.

    From the skin: infrequently sweating, papular rash; rarely cold sweating, hives; frequency unknown - edema of the face, itching, Stevens-Johnson syndrome.

    Laboratory and instrumental data: infrequently - increased activity of alanine aminotransferase, creatine phosphokinase, aspartate aminotransferase; rarely - an increase in the concentrations of glucose and creatinine of the blood, a decrease in the concentration of potassium blood.

    Other: often - fatigue, swelling, including peripheral, feeling of "intoxication", violation of gait; infrequently - asthenia, falls, thirst, a feeling of restraint in the chest, pain, pathological sensations, chills; rarely - generalized edema, hyperthermia.

    Overdose:

    Symptoms: the most frequent undesirable phenomena developing with an overdose of pregabalin were: affective disorders, drowsiness, confusion, depression, agitation and anxiety.

    Treatment: gastric lavage, reception of activated charcoal, maintenance treatment and, if necessary, hemodialysis.

    Interaction:

    Because the pregabalinum is excreted by the kidneys mainly in the unchanged form, undergoes minimal metabolism in the human body (in the form of metabolites, less than 2% of the dose is excreted by the kidneys), does not inhibit the metabolism of other medicinal substances in vitro and does not bind to plasma proteins, it is unlikely that pregabalinum can enter into pharmacokinetic interaction with other drugs.

    Drugs that depress the central nervous system

    There have been reports of violations of breathing and the onset of coma with the simultaneous use of pregabalin with other drugs that depress the central nervous system.

    Opioid analgesics

    Also reported was the negative effect of pregabalin on the activity of the gastrointestinal tract (including the development of intestinal obstruction, paralytic ileus, constipation) with concomitant use with drugs that cause constipation (such as opioid analgesics).

    Oxycodone + Lorazepam + Ethanol

    Pregabalin can enhance the effects of ethanol and lorazepam. Repeated oral administration of pregabalin with oxycodone, lorazepam or ethanol did not have a clinically significant effect on respiration. Pregabalin, apparently, enhances the violations of cognitive and motor functions caused by oxycodone.

    Oral contraceptives

    When using oral contraceptives containing norethisterone and / or ethinyl estradiol, simultaneously with pregabalin, the equilibrium pharmacokinetics of both drugs did not change.

    There were no signs of clinically significant pharmacokinetic interaction of pregabalin with phenytoin, carbamazepine, valproic acid, lamotrigine, gabapentin, lorazepam, oxycodone and ethanol.

    It has been established that oral hypoglycemic agents, diuretics, insulin, phenobarbital, tiagabine and topiramate have no clinically significant effect on the clearance of pregabalin.

    Special instructions:

    From the side of metabolism

    A part of patients with diabetes mellitus in case of weight gain on the background of treatment with Pregabalin Canon may require correction of doses of hypoglycemic agents.

    From the nervous system

    Treatment with Pregabalin Canon can be accompanied by dizziness and drowsiness, which increases the risk of accidental injuries (falls) in the elderly. Cases of loss of consciousness, confusion of consciousness and violation of cognitive functions were also noted. Therefore, until patients do not evaluate the possible effects of the drug, they must be careful.

    Information on the possibility of canceling other anticonvulsants with suppression of seizures with pregabalin and the advisability of monotherapy with this drug are insufficient. There are reports of the development of seizures, including epileptic status and minor seizures with pregabalin or immediately after therapy.

    The frequency of central nervous system (CNS) adverse events, especially such as drowsiness, is increased in the treatment of central neuropathic pain caused by spinal cord injury, which, however, may result from the summation of the effects of pregabalin and other concurrent agents (eg, antispastic). This circumstance should be taken into account when prescribing Pregabalin Kanon for this indication.

    There have been cases of encephalopathy, especially in patients with concomitant diseases, which can lead to the development of encephalopathy.

    From the sense organs

    With the treatment with Pregabalin Canon, there may be abnormalities on the part of the visual organ, which in most cases pass independently both during the continuation of treatment and when pregabalin is withdrawn.

    From the urinary system

    There were also cases of development of renal failure, which was reversible after the discontinuation of pregabalin therapy.

    From the side of the cardiovascular system

    There was reported the development of chronic heart failure against the background of pregabalin therapy in some patients. These reactions were predominantly observed in elderly patients with cardiac impairment and who received the drug for neuropathy. Therefore, Pregabalin Kanon should be used with caution in this category of patients. After the withdrawal of the drug, the disappearance of the manifestations of such reactions is possible.

    Interaction with opioid analgesics

    In case of simultaneous use of Pregabalin Canon with opioid analgesics, preventive measures of constipation and intestinal obstruction should be taken, in particular in elderly patients (see section "Interaction with other medicinal products").

    Allergic reactions

    Preparation Pregabalin The cannon must be discontinued if symptoms of angioedema develop (such as facial swelling, perioral edema, or swelling of the upper respiratory tract).

    The "cancellation" syndrome

    Before starting therapy, the patient should be informed of the possible development of withdrawal syndrome after discontinuation of treatment with Pregabalin Canon.

    There are reports of cases of development of dependence when using pregabalin. Patients with drug dependence in a history need careful medical observation for symptoms of dependence on pregabalin.

    Other

    Antiepileptic drugs, including Pregabalin Canon, may increase the risk of suicidal thoughts or behavior. Therefore, patients receiving these drugs should be carefully monitored for the appearance or deterioration of depression, the appearance of suicidal thoughts or behavior.

    Effect on the ability to drive transp. cf. and fur:

    Preparation Pregabalin Canon can cause dizziness, drowsiness, as well as violations from the visual organ and, accordingly, affect the ability to drive vehicles and mechanisms. Patients should refrain from managing vehicles and mechanisms or carry out other potentially hazardous activities that require an increased concentration of attention and speed of psychomotor reactions, until it becomes clear,whether this drug affects the performance of such tasks.

    Form release / dosage:

    Capsules, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 300 mg.

    Packaging:

    By 7, 10, 14 or 15 capsules in a contour mesh box made of polyvinylchloride film and aluminum foil printed lacquered.

    For 2, 4, 6, 8 contour cell packs of 7 capsules or 1, 2, 3, 4 contour packs of 10 or 14 capsules or 2 contour packs of 15 capsules together with the instructions for use are placed in a pack of cardboard .

    Storage conditions:

    In a dry, protected from light place at a temperature of no higher than 25 ° C.

    Keep out of the reach of children.

    Shelf life:

    2 years.

    Do not use after the expiration date.

    Terms of leave from pharmacies:On prescription
    Registration number:LP-002530
    Date of registration:09.07.2014
    The owner of the registration certificate:CANONFARMA PRODUCTION, CJSC CANONFARMA PRODUCTION, CJSC Russia
    Manufacturer: & nbsp
    Representation: & nbspCANONFARMA PRODUCTION CJSC CANONFARMA PRODUCTION CJSC Russia
    Information update date: & nbsp27.08.2015
    Illustrated instructions
      Instructions
      Up